Drugs / Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01945814 | Feb 2014 → Oct 2017 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Catherine Bollard | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) | “Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)” NCT01945814 ↗ |
| Action | Deplete | “T lymphocytes can kill viral cells” NCT01945814 ↗ |
| Modality | Cell therapy | “Adoptive cellular therapy with virus-specific T cells (VSTs) has been successful in preventing or treating targeted viruses in prior studies” PMID 31219185 ↗ Jun 2019 |